LUGPA Policy Brief: Enhancing Healthcare Price Transparency and Cost ReductionSept. 14, 2023 The LCMTA amalgamates elements from various proposed bills considered by the U.S. House in 2023, each designed to tackle specific healthcare issues individually. This new proposal stems from extensive negotiations involving the House Ways & Means, Energy & Commerce, and Education & Workforce Committees. Policy Highlights: Title I - Improving Health Care Transparency:
Additionally, the bill compels Pharmacy Benefit Managers (PBMs) to provide employers with comprehensive prescription drug spending data. The Government Accountability Office (GAO) is entrusted with reporting on healthcare price transparency requirements and their practical impact. A study examining the ramifications of vertical integration in Medicare Advantage organizations, providers, PBMs, and pharmacies is mandated. Furthermore, the bill establishes an advisory committee to enhance the accessibility and usability of information collected under this act and the Consolidated Appropriations Act of 2021. Title II - Reducing Health Care Costs for Patients:
Title III - Supporting Patients, Health Care Workers, Community Health Centers, and Hospitals:
Title IV - Increasing Access to Quality Health Data and Lowering Hidden Fees:
Collectively, these provisions strive to improve healthcare price transparency, empower patients, and alleviate costs across the healthcare spectrum. By granting consumers more comprehensive access to pricing information, the LCMTA aspires to foster a healthcare environment that is both highly competitive and patient centric. LUGPA has been actively engaged, providing comments and letters to Congress on several bills incorporated into the LCMTA. A full copy of the proposed bill is available here, and a summary is available here.
|